Leap Therapeutics, Inc. (LPTX)

3,1600 -0,1100 (-3,36%) In data: 12:25PM EDT. Mercato aperto.

Leap Therapeutics, Inc.

47 Thorndike Street
Suite B1-1
Cambridge, MA 02141
United States
617 714 0360
https://www.leaptx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 54

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Douglas E. Onsi J.D.	CFO, General Counsel, Treasurer & Secretary, President, CEO & Director	1,04M	N/D	1969
Mr. Augustine J. Lawlor	Chief Operating Officer	713,57k	N/D	1957
Dr. Jason S. Baum Ph.D.	Chief Scientific Officer	N/D	N/D	1979
Mr. Mark O'Mahony	Chief Manufacturing Officer	N/D	N/D	1971
Ms. Christine M. Granfield	VP and Head of Regulatory Affairs & Quality	N/D	N/D	1968

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Leap Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.